Precision Optics Corporation, Inc. — FY2014 Form 10-K
Reporting period: Fiscal year ended June 30, 2014, compared with fiscal 2013. Although the request metadata refers to 2013 Q4, this filing reports full-year fiscal 2014 results. The company designs and manufactures optical products, primarily medical endoscopes, endocouplers, micro-optics and camera assemblies; approximately 10% of its business is military and industrial.
Financial performance and liquidity
| Metric | FY2014 | FY2013 |
|---|---|---|
| Revenue | $3,651,181 | $2,519,743 |
| Gross profit / margin | $800,795 / 21.9% | $654,428 / 26.0% |
| Operating loss | $1,159,726 | $1,232,509 |
| Net loss | $1,160,638 | $1,787,680 |
| Basic and diluted loss per share | $0.26 | $0.51 |
| Net cash used in operations | $886,031 | $1,293,392 |
| Cash and cash equivalents at year-end | $202,380 | $1,034,587 |
- Revenue rose 44.9%, driven by higher sales of endocouplers, endoscopes and micro-optics, plus initial scanning otoscope and 120-degree fiber-scope sales; lower sales of a spinal-surgery visualization system partly offset growth.
- Gross margin fell to 21.9%, mainly due to product mix and nonrecurring manufacturing startup costs for new products. R&D expense, net, declined 25.3% to $471,106; SG&A rose 19.2% to $1,503,443, reflecting higher legal, consulting, stock-compensation and selling costs.
- Current assets were $1,814,229 and current liabilities $1,095,877 at year-end, versus $2,271,027 and $592,886, respectively, in 2013. Accounts payable increased to $715,192 from $289,255. The balance sheet lists no debt at June 30, 2014; prior convertible notes had been settled. The filing does not provide a separate debt or borrowing-facility balance.
- Operating cash use improved year over year but remained substantial. Investing activities provided $3,824; financing activities provided $50,000, an advance against the subsequent private placement. Capital equipment purchases were $1,680.
Material changes, outlook and risks
- The company reported continuing operating losses and said losses were expected to continue until sales reached breakeven and profitable levels. Management warned that additional debt or equity financing or a strategic alliance might be needed; financing might not be available on acceptable terms.
- After year-end, the company sold 1,717,152 shares at $0.60 per share, for $1,030,291 gross proceeds, primarily for working capital. $50,000 was received before year-end and the remainder in July 2014. The placement triggered anti-dilution adjustments that increased certain warrant share amounts and reduced exercise prices.
- Management described commercialization opportunities in Microprecision lenses, micro medical cameras and handheld 3D endoscopes. It reported production shipments against a $1,032,000 endoscope order, initial production orders for a 3D ophthalmologic adapter after year-end, and expected production launches for other customer projects. The timing and pace of future revenue growth remained uncertain; no quantified revenue or earnings guidance was provided.
- Customer concentration remains material: the three largest customers generated 21%, 21% and 14% of FY2014 revenue; approximately 75% of sales went to the top six customers. The three largest customers represented 30%, 17% and 11% of receivables at year-end.
- Other key risks include fixed-price orders that may prove unprofitable, dependence on a small number of suppliers for optical glass and outsourced processing, regulatory requirements, competition from better-resourced companies, product-development and market-acceptance uncertainty, and potential dilution. Outstanding warrants covered 2,983,752 shares at a weighted-average exercise price of $1.25 at June 30, 2014.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at June 30, 2014, citing material weaknesses related to segregation of accounting duties and inventory valuation. The company reported remediation procedures but did not conclude that the weaknesses had been resolved.
- Unusual prior-period items included a $629,000 noncash charge for settling liquidated-damages claims in FY2013 and a $76,149 gain from settling accounts payable in FY2013; both affected comparability with FY2014. The independent auditor issued an unmodified opinion on the financial statements and did not audit internal-control effectiveness.
Most important facts for investors to verify
- Cash runway and working-capital needs after the July 2014 equity raise, including actual net proceeds and subsequent cash use.
- Whether new-product orders convert to sustained production revenue and improve gross margins, including customer timing and order concentration.
- Progress and independent validation of remediation for the disclosed material weaknesses in financial reporting controls.
- Current fully diluted share count and the impact of the placement, warrant anti-dilution provisions, outstanding warrants and options.
- Customer receivable collections, inventory recoverability and continued access to key optical materials and outside processing.